Statin drugs markedly inhibit testosterone production by rat Leydig cells in vitro: Implications for men

Reproductive Toxicology

Volumn 45, Issue , 2014, Pages 52-58

  Klinefelter, G R ^a   Laskey, J W ^a   Amann, R P ^b  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b Department of Ecosystem Science and Sustainability   (United States)

Author keywords

Isolated Leydig cells; LH stimulation; Progestin; Statins; Testosterone production

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LUTEINIZING HORMONE; PREGNENOLONE; PROGESTERONE; TESTOSTERONE;

ANIMAL; CELL CULTURE; DRUG EFFECTS; LEYDIG CELL; MALE; METABOLISM; SPRAGUE DAWLEY RAT; TOXICITY;

ANIMALS; CELLS, CULTURED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEYDIG CELLS; LUTEINIZING HORMONE; MALE; PREGNENOLONE; PROGESTERONE; RATS, SPRAGUE-DAWLEY; TESTOSTERONE;

EID: 84893479853     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2013.12.010     Document Type: Article

References (54)

1. Endo A., Kuroda M., Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterol produced by Penicillium citrinum. J Antibiot 1976, 29:1346-1348.
2. Endo A., Kuroda M., Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976, 72:323-326.
3. Endo A., Tsujita Y., Kuroda M., Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem 1977, 77:31-36.
4. Alberts A.W. Discovery, biochemistry and biology of lovastatin. Am J Cardiol 1988, 62:10J-15J.
5. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992, 33:1569-1582.
6. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B 2010, 86:484-493.
7. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fund Clin Pharmacol 2004, 19:117-125.
8. Clendening J.W., Penn L.Z. Targeting tumor cell metabolism with statins. Oncogene 2012, 1-12. [Epub ahead of print]. 10.1038/onc.2012.6.
9. Shitara Y., Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112:71-105.
10. Weng T.-C., Kao Yang Y.-H., Lin S.-J., Tai S.-H. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010, 35:139-151.
11. Stocco D.M., McPhaul M.J. Physiology of testicular steroidogenesis. Physiology of reproduction 2006, 977-1016. Elsevier, San Diego. E. Knobil, J. Neill (Eds.).
12. Reaven E., Zhan L., Nomoto A., Leers-Sucheta S., Azhar S. Expression and microvillar localization of scavenger receptor class B, type I (SR-B1) and selective cholesteryl ester uptake in Leydig cells from rat testis. J Lipid Res 2000, 41:343-356.
13. Miller W., Bose H.S. Early steps in steroidogenesis: intracellular cholesterol trafficking. J Lipid Res 2011, 5(2):2111-2135.
14. Endo A., Tsujita Y., Kuroda M., Yanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 1979, 575:266-276.
15. Bocan T.M.A., Ferguson E., McNally W., Uhlendorf P.D., Mueller S.B., Dehart P., et al. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981; comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta 1992, 1123:133-144.
16. Germershausen J.I., Hunt V.M., Bostedor R.G., Bailey P.J., Karkas J.D., Alberts A.W. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 1989, 158:667-675.
17. Liu P.Y., Veldhuis J.D. The hypothalamo-pituitary unit, testes, and male accessory organs. Yen and Jaffe's reproductive endocrinology: physiology, pathophysiology, and clinical management 2009, 283-298. Elsevier, Philadelphia. 6th ed. F. Strauss, R.L. Barbieri (Eds.).
18. Schooling C.M., Yeung S.L.A., Freeman G., Cowling B.J. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med 2013, 11:57. 10.1186/1747-7015/11/57.
19. Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001, 86:724-731.
20. Araujo A.B., O'Donnell A.B., Brambilla D.J., Simpson W.B., Longcoipe C., Matsumoto A.M., et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004, 89:5920-5926.
21. Liu P.Y., Beilin J., Meier C., Nguyen T.V., Center J.R., Leedman P.J., et al. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab 2007, 92:3599-3603.
22. Wu F.C.W., Tajar A., Pye S.R., Silman A.J., Finn J.D., O'Neill T.W., et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008, 9(3):2737-2745.
23. Rohrmann S., Platz E.A., Selvint E., Shielst M.S., Joshut C.E., Menket A., et al. The prevalence of low sex steroid hormone concentrations in men in the Third National Health and Nutrition Survey (NHANES). Clin Endocrinol 2011, 75:232-239.
24. Kerr J.B., Loveland K.L., O'Bryan M.K., de Kretser D.M. Cytology of the testis and intrinsic control mechanisms. Physiology of reproduction 2006, 827-947. Elsevier, San Diego. 3rd ed. E. Knobil, J. Neill (Eds.).
25. O'Donnell L., Meachem S.J., Stanton P.G., McLachlan R.I. Endocrine regulation of spermatogenesis. Physiology of reproduction 2006, 1017-1069. Elsevier, San Diego. 3rd ed. E. Knobil, J. Neill (Eds.).
26. Chen H., Midzak A., Luo L.-D., Zirkin B.R. Aging and the decline of androgen production. Contemporary endocrinology: the Leydig cell in health and disease 2007, 117-131. Humana Press, Totowa, NJ. A.H. Payne, M.P. Hardy (Eds.).
27. Gibson D.M., Bron N.J., Richens A., Hounslow N.J., Sedman A.J., Whitfield L.R. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996, 36:242-246.
28. Benotti M.J., Trenholm R.A., Vanderford B.J., Holady J.C., Stanford B.D., Snyder S.A. Pharmaceuticals and endocrine disrupting compounds in US drinking water. Environ Sci Technol 2009, 43:597-603.
29. World Health Organization Pharmaceuticals in drinking water. WHO/HSE/WSH/11.05 2011, 1-49.
30. Klinefelter G.R. Male infertility and the environment: a plethora of associations based on a paucity of meaningful data. Surgical and medical management of male infertility 2013, 249-256. Cambridge University Press, Cambridge. M. Goldstein, P.N. Schlegel (Eds.).
31. Van Vliet A.K., van Thiel G.C.F., Naaktgeboren N., Cohen L.H. Vastatins have a distinct effect on sterol synthesis and progesterone secretion in human granulosa cells in vitro. Biochim Biophys Acta 1996, 301:237-241.
32. Izquierdo S., Foyouzi N., Kwintkiewicz J., Duleba A.J. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 2004, 82(Suppl. 3):1193-1197.
33. Klinefelter G.R., Hall P.F., Ewing L.L. Effect of luteinizing hormone deprivation in situ on steroidigenesis of rat Leydig cells purified by a multistep procedure. Biol Reprod 1987, 36:769-783.
34. Klinefelter G.R., Ewing L.L. Optimizing testosterone production by purified adult rat Leydig cells in vitro. In Vitro Cell Dev Biol 1988, 24:545-549.
35. Klinefelter G.R., Laskey J.W., Roberts N.L. In vitro/in vivo effects of ethane dimethane sulfonate on Leydig cells of adult rats. Toxicol Appl Pharmacol 1991, 107:460-471.
36. Tavert C., Fofana M., Carreau S., Le Goff D. Rat Leydig cells use apolipoprotein E depleted high density lipoprotein to regulate testosterone production. Mol Cell Biochem 2000, 213:51-59.
37. Parker R.A., Clark R.W., Sit S.-Y., Lanier T.L., Grosso R.A., Wright J.J.K. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res 1990, 31:1271-1282.
38. Koga T., Shimada Y., Kuroda M., Tsujita Y., Hasegawa K., Yamazaki M. Tissue selective inhibition of cholesterol synthesis in vivo by parvastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1990, 1045:115-120.
39. Koga T., Fukuda K., Shimada Y., Fukami M., Koike H., Tsujita Y. Tissue selectivity of paravastatin sodium, lovastatin and simvastatin: relationship between inhibition of de novo sterol synthesis and active drug concentration in the liver, spleen and testis in rat. Eur J Biochem 1992, 209:315-319.
40. Dostal L.A., Whitfield L.R., Anderson J.A. Fertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatin. Fund Appl Toxicol 1996, 32:285-292.
41. Dostal L.A., Juneau P., Rothwell C.E. Repeated analysis of semen parameters in Beagle dogs during a 2-year study with HMG-CoA reductase inhibitor, atorvastatin. Toxicol Sci 2001, 61:128-134.
42. Gerson R.J., MacDonald J.S., Alberts A.W., Kornburst D.J., Majka J.A., Stubbs R.J., et al. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am J Med 1989, 87(Suppl. 4A):28S-38S.
43. Moskovic D.J., Araujo A.B., Lipshultz L.I., Khera M. The 20-year public health impact and direct cost of testosterone deficiency in U.S. men. J Sex Med 2012, [Epub ahead of print]. 10.1111/j.1743-6109.2012.02944x.
44. Pirke K.M., Sintermann R., Vogt H.-J. Testosterone and testosterone precursors in the spermatic vein and in the testicular tissue of old men. Gerontology 1980, 26:221-230.
45. Takahashi J., Higashi Y., LaNasa J.A., Yoshida K.-I., Winters S.J., Oshima H., et al. Studies of the human testis. XVIII. Simultaneous measurement of nine intratesticular steroids: evidence for reduced mitochondrial function in testes of elderly men. J Clin Endocrinol Metab 1983, 56:1178-1187.
46. Corona G., Boddi V., Balercia G., Rastrelli G., De Vita G., Sforza G., et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med 2010, 7:1547-1556.
47. Alberts A.W., Chen J.C., Kuron G., Hunt V., Huff J., Hoffman C., et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980, 77:3957-3961.
48. Hu J., Zhang Z., Shen W.-J., Azhar S. Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab 2010, 7:47-72.
49. Lieberman S. The generally accepted version of steroidogenesis is not free of uncertainties: other tenable and possible superior renditions may be invented. Steroid Biochem Mol Biol 2008, 109:197-199.
50. Payne A.H., Hales D.B. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Res 2004, 25:947-970.
51. Slaunwhite W.R., Burgett M.J. In vitro testosterone synthesis by rat testicular tissue. Steroids 1965, 6:721-735.
52. Chubb C., Ewing L.L. Steroid secretion by in vitro perfused testes: secretions of rabbit and rat testes. Am J Physiol Endocrinol Metab 1979, 237:E231-E238.
53. Chubb C., Ewing L.L. Steroid secretion by in vitro perfused testes: testosterone biosynthetic pathways. Am J Physiol Endocrinol Metab 1979, 237:E247-E254.
54. Eacker S.M., Agrawal N., Qian K., Dichek H.L., Gong E.Y., Lee K., et al. Hormonal regulation of testicular steroid and cholesterol homeostatis. Mol Endocrinol 2008, 22:623-635.